The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status

被引：0
|
作者：
Wolfgang J. Köstler
Thomas Brodowicz
Gernot Hudelist
Margaretha Rudas
Reinhard Horvat
Günther G. Steger
Christian F. Singer
Johannes Attems
Werner Rabitsch
Negar Fakhrai
Katarzyna Elandt
Christoph Wiltschke
Michael Hejna
Christoph C. Zielinski
机构：
[1] Medical University of Vienna,Clinical Division of Oncology, Department of Medicine I
[2] Medical University of Vienna,Center of Excellence for Clinical & Experimental Oncology (CLEXO)
[3] Medical University of Vienna,Ludwig Boltzmann Institute for Clinical Experimental Oncology
[4] Medical University of Vienna,Clinical Institute of Pathology
[5] Medical University of Vienna,Clinical Division of Special Gynecology, Department of Gynecology and Obstetrics
[6] Otto Wagner Hospital,Department of Pathology
[7] Medical University of Vienna,Bone Marrow Transplantation Unit, Department of Medicine I
来源：
Journal of Cancer Research and Clinical Oncology | 2005年 / 131卷
关键词：
Her-2/; Breast cancer; p53; Trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose: Her-2/neu and p53-mediated signalling have been shown to interact at various cellular levels. However, the clinical relevance of p53 alterations in patients receiving trastuzumab for Her-2/neu-overexpressing metastatic breast cancer (MBC) remains unknown. The present study was performed to corroborate previous in vitro findings from our laboratory showing that trastuzumab induces growth arrest and apoptosis in a p53-independent manner.
引用
收藏
页码：420 / 428
页数：8
相关论文
共 50 条
  • [1] The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status
    Köstler, WJ
    Brodowicz, T
    Hudelist, G
    Rudas, M
    Horvat, R
    Steger, GG
    Singer, CF
    Attems, J
    Rabitsch, W
    Fakhrai, N
    Elandt, K
    Wiltschke, C
    Hejna, M
    Zielinski, CC
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (07) : 420 - 428
  • [2] Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/NEU-overexpressing metastatic breast cancer
    Sawaki, M
    Ito, Y
    Tada, K
    Mizunuma, N
    Takahashi, S
    Horikoshi, N
    Kasumi, F
    Akiyama, F
    Sakamoto, G
    Imai, T
    Nakao, A
    Hatake, K
    TUMORI JOURNAL, 2004, 90 (01): : 40 - 43
  • [3] Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review
    Madarnas, Yolanda
    Trudeau, Maureen
    Franek, Jacob A.
    McCready, David
    Pritchard, Kathleen I.
    Messersmith, Hans
    CANCER TREATMENT REVIEWS, 2008, 34 (06) : 539 - 557
  • [4] The epidemiology of Her-2/neu and P53 in breast cancer
    Bernstein, JL
    López-Carrillo, L
    Wang, L
    SALUD PUBLICA DE MEXICO, 1999, 41 : S114 - S123
  • [5] Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
    Brodowicz, T
    Kandioler, D
    Tomek, S
    Ludwig, C
    Rudas, M
    Kunstfeld, R
    Koestler, W
    Hejna, M
    Budinsky, A
    Krainer, M
    Wiltschke, C
    Zielinski, CC
    BRITISH JOURNAL OF CANCER, 2001, 85 (11) : 1764 - 1770
  • [6] Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
    T Brodowicz
    D Kandioler
    S Tomek
    C Ludwig
    M Rudas
    R Kunstfeld
    W Koestler
    M Hejna
    A Budinsky
    C Wiltschke
    C C Zielinski
    British Journal of Cancer, 2001, 85 : 1764 - 1770
  • [7] In vitro and in vivo effects of fulvestrant combined with trastuzumab in breast cancer with estrogen receptor-positive and HER-2/neu-overexpressing
    Chen, Q.
    Wu, K.
    Lu, Y.
    Ding, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S121 - S122
  • [8] Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    SEMINARS IN ONCOLOGY, 1999, 26 (04) : 78 - 83
  • [9] The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer
    Joe Yujiao Chang
    Weiya Xia
    Ruping Shao
    Frank Sorgi
    Gabriel N Hortobagyi
    Leaf Huang
    Mien-Chie Hung
    Oncogene, 1997, 14 : 561 - 568
  • [10] Vinorelbine and trastuzumab enhance effector cell function in patients with HER-2/neu overexpressing metastatic breast cancer
    Schwartz, GN
    Kaufman, PA
    Tretter, CPG
    Arrick, BA
    Mulrooney, TJ
    Connelly, EM
    Mellinger, DL
    Fisher, JL
    Ernsloff, MS
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S128 - S128
12345